Tempest Therapeutics Upgraded to Buy After Strategic CAR-T Acquisition
H.C. Wainwright upgrades Tempest Therapeutics to Buy, citing a smart CAR-T acquisition that extends cash runway and strengthens its pipeline.
/ 907 items
#Healthcare↓
Corcept's Experimental Drug Shows Promise in Extending Life for Ovarian Cancer Patients
Corcept Therapeutics' (CORT) relacorilant combined with chemotherapy reduced death risk by 35% in platinum-resistant ovarian cancer patients, with FDA decision expected July 2026.
Janux Therapeutics Partners with Bristol Myers Squibb in Major Cancer Drug Deal
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Greenwich LifeSciences Stock Surges on FDA Approval for Breast Cancer Trial
Greenwich LifeSciences (GLSI) shares jump 42% after FDA approves commercial GP2 for Phase III breast cancer prevention trial, reducing regulatory risks ahead of license application.
TD Cowen Downgrades Legend Biotech After Carvykti Sales Miss
TD Cowen cut Legend Biotech to Hold from Buy after weaker Carvykti sales, citing slower demand, safety concerns, and rising competition.
Moderna Surges 69% in 2026 as Cancer Vaccine Shows Five-Year Melanoma Survival Benefits
Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.